Ramm Pharma Corp

Chart & Performance

D1W1MN

P/E

—

P/S

1.37

EPS

—

Div Yield, %

—

Shrs. gr., 5y

18.82%

Rev. gr., 5y

-5.00%

Revenues

-14.28%

Net income

-17m

L+113.73%

CFO

-4m

L-8.89%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.

URL

http://rammpharma.com/

IPO date

Nov 08, 2019

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CAD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title CAD in thousands, except ratios and share amounts	2024‑10	2023‑10	2022‑10	2021‑10	2020‑10	2019‑10	2018‑10
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT